| scholarly article | Q13442814 |
| P50 | author | Robert H. Purcell | Q2157414 |
| Ronald Engle | Q70196779 | ||
| Suzanne U. Emerson | Q109868474 | ||
| Sugantha Govindarajan | Q113303675 | ||
| P2093 | author name string | Hanh Nguyen | |
| Max Shapiro | |||
| William C. Blackwelder | |||
| Jean Paul Prieels | |||
| Doris C. Wong | |||
| Ronald E. Engle | |||
| P2860 | cites work | Identification by phage display and characterization of two neutralizing chimpanzee monoclonal antibodies to the hepatitis E virus capsid protein | Q33180421 |
| Genetic and experimental evidence for cross-species infection by swine hepatitis E virus | Q33786012 | ||
| Comparative pathogenesis of infection of pigs with hepatitis E viruses recovered from a pig and a human | Q33971491 | ||
| Hepatitis E virus epidemiology in industrialized countries | Q34215937 | ||
| Animal models of hepatitis A and E. | Q34282845 | ||
| Successful passive and active immunization of cynomolgus monkeys against hepatitis E | Q35838428 | ||
| ELISA for antibody to hepatitis E virus (HEV) based on complete open-reading frame-2 protein expressed in insect cells: identification of HEV infection in primates | Q41537344 | ||
| Structural characterization of recombinant hepatitis E virus ORF2 proteins in baculovirus-infected insect cells | Q42061077 | ||
| Genetic heterogeneity of hepatitis E virus | Q42658572 | ||
| Identification and characterization of the neutralization epitope(s) of the hepatitis E virus | Q43767391 | ||
| Immunogenicity and protective efficacy of a vaccine prepared from 53 kDa truncated hepatitis E virus capsid protein expressed in insect cells | Q43819290 | ||
| Sample size and power for prospective analysis of relative risk | Q44928816 | ||
| Report of a collaborative study to assess the suitability of a reference reagent for antibodies to hepatitis E virus | Q45733752 | ||
| A hepatitis E virus variant from the United States: molecular characterization and transmission in cynomolgus macaques | Q45750527 | ||
| Infectivity titration of a prototype strain of hepatitis E virus in cynomolgus monkeys | Q45780293 | ||
| Association of hepatitis E virus with an outbreak of hepatitis in Pakistan: serologic responses and pattern of virus excretion | Q45866479 | ||
| Recombinant vaccine against hepatitis E: duration of protective immunity in rhesus macaques. | Q52598828 | ||
| Recombinant vaccine against hepatitis E: dose response and protection against heterologous challenge. | Q53961708 | ||
| Perspectives of vaccination against hepatitis E | Q74389243 | ||
| P433 | issue | 19-20 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | vaccine | Q134808 |
| hepatitis E | Q326643 | ||
| molecular medicine | Q3523816 | ||
| P304 | page(s) | 2607-2615 | |
| P577 | publication date | 2003-06-01 | |
| 2003-06-02 | |||
| P1433 | published in | Vaccine | Q7907941 |
| P1476 | title | Pre-clinical immunogenicity and efficacy trial of a recombinant hepatitis E vaccine | |
| P478 | volume | 21 |
| Q51525883 | A bacterially expressed particulate hepatitis E vaccine: antigenicity, immunogenicity and protectivity on primates. |
| Q45479898 | A truncated ORF2 protein contains the most immunogenic site on ORF2: antibody responses to non-vaccine sequences following challenge of vaccinated and non-vaccinated macaques with hepatitis E virus |
| Q59360279 | Adaptive Immune Responses in Hepatitis A Virus and Hepatitis E Virus Infections |
| Q45628504 | An ELISA for putative neutralizing antibodies to hepatitis E virus detects antibodies to genotypes 1, 2, 3, and 4. |
| Q92879574 | Animal Models for Hepatitis E virus |
| Q38174398 | Antiviral strategies for hepatitis E virus |
| Q36245120 | Assessment of the cross-protective capability of recombinant capsid proteins derived from pig, rat, and avian hepatitis E viruses (HEV) against challenge with a genotype 3 HEV in pigs |
| Q37630325 | Autochthonous hepatitis e virus infections: a new transfusion-associated risk? |
| Q83026182 | Challenge studies in Rhesus monkeys immunized with candidate hepatitis E vaccines: DNA, DNA-prime-protein-boost and DNA-protein encapsulated in liposomes |
| Q59352246 | Cloning and expression of truncated ORF2 as a vaccine candidate against hepatitis E virus |
| Q26782030 | Current Knowledge on Hepatitis E |
| Q45400020 | Efficient recombinant hepatitis E virus vaccine: mission accomplished? |
| Q37389167 | Epidemiology of hepatitis E virus in the United States: results from the Third National Health and Nutrition Examination Survey, 1988-1994 |
| Q37278231 | Hepatitis E vaccine |
| Q41089524 | Hepatitis E vaccine immunization for rabbits to prevent animal HEV infection and zoonotic transmission |
| Q35826279 | Hepatitis E vaccines: progress and prospects |
| Q37375936 | Hepatitis E virus: Current epidemiology and vaccine |
| Q45324469 | Hepatitis E virus: advances and challenges |
| Q34264481 | Hepatitis E: a complex and global disease |
| Q37320904 | Hepatitis E: an emerging infection in developed countries. |
| Q34334086 | Hepatitis E: an overview and recent advances in vaccine research. |
| Q37544940 | Host immune status and response to hepatitis E virus infection. |
| Q52659699 | Immunization against Hepatitis E. |
| Q45404731 | Immunogenicity of candidate hepatitis E virus DNA vaccine expressing complete and truncated ORF2 in mice |
| Q90345636 | In vivo models for studying Hepatitis E virus infection; Updates and applications |
| Q39932586 | Induction of antibody response against hepatitis E virus (HEV) with recombinant human papillomavirus pseudoviruses expressing truncated HEV capsid proteins in mice. |
| Q59349514 | Life cycle and morphogenesis of the hepatitis E virus |
| Q37103536 | Macaque models of human infectious disease |
| Q34942241 | Molecular biology and pathogenesis of hepatitis E virus |
| Q31024666 | Monoclonal antibodies that neutralize HEV recognize an antigenic site at the carboxyterminus of an ORF2 protein vaccine |
| Q54229856 | Nonhuman Primate Models of Hepatitis A Virus and Hepatitis E Virus Infections. |
| Q59350268 | Nonhuman primate models of human viral infections |
| Q37854151 | Pathogenetic elements of hepatitis E and animal models of HEV infection |
| Q92808828 | Prophylactic Hepatitis E Vaccines: Antigenic Analysis and Serological Evaluation |
| Q45410567 | Protection of chickens against avian hepatitis E virus (avian HEV) infection by immunization with recombinant avian HEV capsid protein |
| Q39453500 | Protective role of humoral immune responses during an outbreak of hepatitis E in Egypt |
| Q42212470 | Robust manufacturing and comprehensive characterization of recombinant hepatitis E virus-like particles in Hecolin(®). |
| Q36023562 | Seroprevalence of hepatitis E virus infection, rural southern People's Republic of China |
| Q33812653 | Subviral particle as vaccine and vaccine platform |
| Q33279839 | T-cell epitope mapping of ORF2 and ORF3 proteins of human hepatitis E virus |
| Q43997251 | The first experimental study on a candidate combined vaccine against hepatitis A and hepatitis E. |
| Q45185642 | The incidence of hepatitis E virus infection in the general population of the USA |
| Q37881208 | Toward the development of a hepatitis E vaccine |
| Q37405170 | Using improved technology for filter paper-based blood collection to survey wild Sika deer for antibodies to hepatitis E virus |
| Q51784137 | Vaccine Development against Zoonotic Hepatitis E Virus: Open Questions and Remaining Challenges. |
| Q37792984 | Viral nanoparticles and virus-like particles: platforms for contemporary vaccine design |
| Q36602264 | Virus-like particles: passport to immune recognition |
| Q46237020 | Zoonotic Hepatitis E Virus: An Ignored Risk for Public Health |
Search more.